計算病理學市場規模、佔有率和趨勢分析：按產品/服務、部署模式、應用、最終用戶和地區分類 - 全球機會分析和行業預測

全球計算病理學市場預計在2026年達到8億美元，並預計到2036年將達到20.6億美元。預計在預測期內，該市場將以9.9%的CAGR成長。本報告全面評估了快速發展的數位化和人工智慧主導的診斷領域，該領域變革傳統的病理學工作流程。報告檢驗了整個價值鏈的市場趨勢、技術進步、競爭格局和未來成長機會。

計算病理學從根本上改變診斷醫學，它將診斷領域從傳統的手工顯微鏡檢查轉變為基於全切片成像和複雜圖像分析演算法的先進人工智慧驅動的數位化工作流程。隨著全球醫療保健產業面臨日益沉重的癌症負擔和專業病理學家嚴重短缺的困境，計算工具對於提高診斷的準確性、處理能力和可重複性非常重要。世界各地的醫院、製藥公司和研究機構正擴大採用這些平台來識別細微的形態學特徵並應對日益成長的檢測量。

本報告提供詳盡的市場評估，分析影響產業成長的技術創新、應用趨勢、監管考量以及不斷變化的競爭格局。報告評估了計算病理學如何重塑診斷工作流程，從人工智慧驅動的組織細分和生物標記定量，到與基因組學和蛋白質組學資料整合以實現全面的精準醫療。本研究還提供策略性市場預測、細分市場洞察和區域分析，以支持明智的商業和投資決策。

市場動態

全球癌症發生率持續攀升，仍是推動市場發展的主要動力。全球檢測量的持續成長，也催生了對更快、更準確、擴充性的檢查室應對日益成長的工作量。人工智慧（AI）和深度學習的不斷進步，提升了演算法識別複雜組織模式的能力，而數位全切片成像掃描儀的日益普及，則為計算分析奠定了更堅實的基礎。

儘管發展動力強勁，但仍有諸多挑戰阻礙其普及。實施完整的計算病理工作流程需要大量的資金投入，包括高速掃描儀、高效能運算基礎設施和大規模儲存，這對小規模檢查室而言仍然是一大障礙。臨床人工智慧演算法的監管環境複雜多變，可能會延緩新產品的上市時間；此外，掃描儀製造商之間缺乏標準化的影像格式，以及與現有實驗室資訊系統整合方面的挑戰，也持續構成技術難題。

儘管如此，該市場仍蘊藏著巨大的長期機會。計算病理學與基因組/蛋白質體學資料的整合正為全面、個人化的精準醫療鋪路，而進入醫療基礎設施快速現代化的新興市場則蘊藏著巨大的成長潛力。伴隨診斷的開發，用於識別最有可能對標靶治療產生反應的患者，為與製藥公司開展合作提供了巨大的潛力；而人工智慧驅動的治療毒性和長期療效預測，也成為另一條成長途徑。

細分市場分析

本報告依產品/服務、部署模式、應用、最終用戶和地區提供詳細的市場分析，幫助相關人員識別高成長業務機會和不斷變化的客戶需求。

依產品和服務分類，軟體佔據最大的市場佔有率，其中包括全切片成像軟體、基於人工智慧的影像分析工具以及支援數位化診斷工作流程的個案管理系統。基於人工智慧的圖像分析軟體是成長最快的細分市場，這主要得益於檢查室中複雜診斷任務自動化程度的不斷提高。就部署模式而言，考慮到大規模大學醫院的資料管理和安全要求，本地部署解決方案目前仍佔據較大佔有率。然而，由於其擴充性和較低的初始基礎設施成本，雲端部署模式正經歷最快的成長。

依應用領域分類，藥物發現與開發佔據最大佔有率，這主要歸功於製藥公司早期採用計算病理學進行生物標記發現和臨床試驗中療效的定量評估。同時，臨床診斷預計將迎來最快成長，因為監管部門的批准日益擴大計算工具在醫院常規癌症診斷中的應用。

區域分析

本報告對北美、歐洲、亞太、拉丁美洲以及中東和非洲市場進行了全面分析。區域評估考慮了影響市場成長的因素，包括研究經費、製藥業的參與度、數位醫療的普及程度以及病理學領域的人才趨勢。

北美目前佔據全球市場最大佔有率，這得益於其雄厚的研發資金、眾多關鍵企業的集中以及對數位醫療技術的早期應用。歐洲則持續保持穩定成長，主要得益於其強大的學術病理學網路以及各主要市場對數位醫療領域不斷擴大的投資。

預計亞太地區將在預測期內實現最快成長，這主要得益於中國和印度等國家診斷基礎設施的快速現代化以及對人工智慧醫療解決方案的大量投資。隨著醫療數位化和癌症治療基礎設施的持續發展，拉丁美洲、中東和非洲地區也將湧現新的商機。

競爭格局

本報告透過檢驗主要市場參與企業的策略定位、掃描器和軟體的整合、人工智慧演算法的能力、夥伴關係關係、收購、區域擴張努力以及近期發展，對競爭格局進行了全面評估。

競爭性基準測試使相關人員能夠根據人工智慧模型的臨床有效性、與不同類型掃描儀的互通性以及策略性舉措來評估公司。本研究還分析了市場參與企業如何透過掃描器製造商和軟體開發人員之間的策略合作來建立無縫的數位化工作流程，以及如何透過持續投資雲端原生架構來提高速度和可擴展性，增強擴充性。

本報告涵蓋的主要公司概況包括：Roche (Ventana Medical Systems)、Danaher Corporation (Leica Biosystems)、Siemens Healthineers AG、GE HealthCare Technologies Inc.、Koninklijke Philips N.V.、Nikon Corporation、Olympus Corporation (Evident)、Hamamatsu Photonics K.K.、Proscia Inc.、Paige.AI、PathAI、Ibex Medical Analytics、Akoya Biosciences、Visiopharm A/S、Indica Labs等。

如何使用此報告

提供計算病理學市場的準確市場規模估算和長期預測。

本研究評估了人工智慧影像分析對診斷準確性和檢查室處理能力的影響。

依產品/服務、部署模式、應用、最終用戶和地區來識別高成長機會。

分析新的技術趨勢、監管發展和創新管道。

根據掃描器和軟體整合、策略舉措和競爭優勢對領先公司進行基準測試。

為產品開發、投資規劃、合作夥伴評估、市場進入和業務擴大策略提供支援。

為醫療設備製造商、醫院、製藥公司、投資者和顧問提供可操作的市場資訊。

主要問題的答案

全球計算病理學市場目前的規模有多大？預計到2036年它將如何發展？

哪些臨床、技術和人口因素推動市場成長？

影響該產業發展的主要促進因素、阻礙因素、機會和挑戰是什麼？

預計哪種產品/服務、部署模式、應用程式、最終用戶或區域細分市場將呈現最強勁的成長？

哪個區域市場蘊藏著最具吸引力的商業機會？

在這個市場中營運的主要公司有哪些？它們採用了哪些競爭策略？

在近期推出的產品、合作、收購和技術創新中，哪些重塑競爭格局？

相關人員如何利用本報告中獲得的市場資訊來支援投資決策、產品開發、競爭基準分析和長期業務策略？

目錄

第1章 市場定義和範圍

第2章 調查方法

第3章 執行摘要

• 基於細分市場的分析
  • 市場分析：依產品/服務分類
  • 市場分析：依部署模式
  • 市場分析：依應用領域
  • 市場分析：依最終用戶分類
  • 市場分析：依地區分類
• 競爭分析

第4章 市場洞察

• 影響市場成長的因素
  • 促進因素
    • 癌症發生率上升和診斷工作量增加
    • 全球範圍內，專業病理學家嚴重短缺
    • 人工智慧和深度學習模型的技術進步
  • 抑制因子
    • 對掃描器計算基礎設施的大量資本投資
    • 臨床人工智慧領域複雜且不斷變化的監管環境
  • 機會
    • 整合多體學資料以實現全面精準醫療
    • 進入亞太和拉丁美洲快速現代化的新興市場
  • 課題
    • 各廠商之間缺乏標準化的影像格式。
    • 大規模患者資料集的資料安全和隱私問題
  • 趨勢
    • 向基於雲端的SaaS 模型過渡，以實現擴充性和協作。
    • 人工智慧在初級臨床診斷領域的法規核准日益增加。
• 波特五力分析
• 監理情勢
• 價值鏈分析

第5章 全球計算病理學市場：依產品與服務分類

• 軟體
  • 全玻片成像（WSI）軟體
  • 基於人工智慧的圖像分析軟體
  • 個案管理系統
• 服務
  • 諮詢和實施
  • 培訓和技術支援

第6章 全球計算病理學市場：依部署模式分類

• 現場
• 雲端（SaaS）

第7章 全球計算病理學市場：依應用分類

• 藥物發現與開發
• 臨床診斷
• 教育/研究

第8章 全球計算病理學市場：依最終用戶分類

• 醫院/診斷檢查室
• 製藥和生物技術公司
• 學術研究機構

第9章 全球計算病理學市場：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 荷蘭
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他拉丁美洲國家
• 中東和非洲

第10章 競爭格局

• 關鍵成長策略
• 競爭儀錶板
• 供應商市場定位
• 2025年市場佔有率分析

第11章 公司簡介

• Roche（Ventana Medical Systems）
• Danaher Corporation（Leica Biosystems）
• Siemens Healthineers AG
• GE HealthCare Technologies Inc.
• Philips Healthcare
• Nikon Corporation
• Olympus Corporation（Evident）
• Hamamatsu Photonics KK
• Proscia Inc.
• Paige.AI
• PathAI
• Ibex Medical Analytics
• Akoya Biosciences, Inc.
• Visiopharm A/S
• Indica Labs, Inc.

第12章 附錄

The global Computational Pathology market is estimated to be valued at USD 0.80 billion in 2026 and is projected to reach USD 2.06 billion by 2036, expanding at a CAGR of 9.9% during the forecast period. The report provides a comprehensive evaluation of the rapidly evolving digital and AI-driven diagnostics landscape transforming traditional pathology workflows, examining market trends, technological advancements, competitive developments, and future growth opportunities across the value chain.

Computational pathology is fundamentally transforming diagnostic medicine by shifting the field from manual microscopy toward advanced, AI-driven digital workflows built on whole-slide imaging and sophisticated image analysis algorithms. As the global healthcare sector faces an escalating cancer burden alongside a critical shortage of specialized pathologists, computational tools have become essential for enhancing diagnostic accuracy, throughput, and reproducibility. Hospitals, pharmaceutical companies, and research institutions across the globe are increasingly adopting these platforms to identify subtle morphological features and manage rising testing volumes.

This report delivers an in-depth assessment of the market by analyzing technological innovations, adoption trends, regulatory considerations, and competitive developments influencing industry growth. It evaluates how computational pathology is reshaping diagnostic workflows, from AI-based tissue segmentation and biomarker quantification to integration with genomic and proteomic data for holistic precision medicine. The study also provides strategic market forecasts, segment-level insights, and regional analysis to support informed business and investment decisions.

Market Dynamics

The rising global incidence of cancer remains one of the primary drivers of the market, creating substantial demand for faster, more accurate, and scalable diagnostic solutions as testing volumes continue to climb worldwide. The persistent global shortage of trained pathology professionals is further accelerating adoption, as computational tools help laboratories manage increasing workloads through automation, image analysis, and clinical decision support. Continuous advancements in artificial intelligence and deep learning are improving the ability of algorithms to identify complex tissue patterns with high consistency, while the expanding installed base of digital whole-slide imaging scanners is broadening the foundation available for computational analysis.

Despite this momentum, several challenges continue to influence adoption. The high capital investment required to implement a full computational pathology workflow, including high-speed scanners, high-performance computing infrastructure, and large-scale storage, remains a significant barrier for smaller laboratories. The complex and evolving regulatory landscape governing clinical AI algorithms can slow time-to-market for new products, and inconsistent image formats across scanner manufacturers, along with integration challenges with existing laboratory information systems, present ongoing technical hurdles.

The market nevertheless presents significant long-term opportunities. The integration of computational pathology with genomic and proteomic data is opening a path toward holistic, personalized precision medicine, while expansion into emerging markets with rapidly modernizing healthcare infrastructure presents substantial growth potential. The development of companion diagnostics that identify patients most likely to respond to targeted therapies offers strong potential for pharmaceutical partnerships, and the use of AI to predict treatment toxicity and long-term outcomes is emerging as a further avenue for growth.

Segment Analysis

The report provides detailed market analysis across product and service, deployment mode, application, end user, and geography, enabling stakeholders to identify high-growth business opportunities and evolving customer requirements.

Based on product and service, software holds the largest share of the market, encompassing whole-slide imaging software, AI-based image analysis tools, and case management systems that enable digital diagnostic workflows, with AI-based image analysis software representing the fastest-growing sub-segment as laboratories increasingly automate complex diagnostic tasks. From a deployment mode perspective, on-premise solutions currently account for the larger share given data control and security requirements at large academic medical centers, while cloud-based models are witnessing the fastest growth due to their scalability and lower upfront infrastructure costs.

Based on application, drug discovery and development accounts for the largest share as pharmaceutical companies were early adopters of computational pathology for biomarker discovery and quantifying treatment effects in clinical trials, while clinical diagnostics is projected to grow fastest as regulatory approvals expand the use of computational tools for routine cancer diagnosis in hospital settings.

Regional Analysis

The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Regional evaluations consider research funding, pharmaceutical industry presence, digital health adoption, and pathology workforce dynamics influencing market growth.

North America currently accounts for the largest share of the global market, supported by robust research funding, a high concentration of leading pharmaceutical companies, and early adoption of digital health technologies. Europe continues to demonstrate steady growth, underpinned by strong academic pathology networks and increasing digital health investment across major markets.

Asia-Pacific is expected to register the fastest growth throughout the forecast period, supported by rapid modernization of diagnostic infrastructure and heavy investment in AI-driven healthcare solutions in countries including China and India. Latin America and the Middle East & Africa are also expected to offer emerging opportunities as healthcare digitalization and cancer care infrastructure continue to expand.

Competitive Landscape

The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of key market participants, their scanner and software integration, AI algorithm capabilities, partnerships, acquisitions, geographic expansion initiatives, and recent business developments.

Competitive benchmarking enables stakeholders to evaluate companies based on clinical validity of AI models, interoperability with different scanner types, and strategic initiatives. The study also analyzes how market participants are strengthening their competitive position through strategic partnerships between scanner manufacturers and software developers to create seamless digital workflows, along with continued investment in cloud-native architectures to improve speed and scalability.

Key companies profiled in the report include Roche (Ventana Medical Systems), Danaher Corporation (Leica Biosystems), Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Nikon Corporation, Olympus Corporation (Evident), Hamamatsu Photonics K.K., Proscia Inc., Paige.AI, PathAI, Ibex Medical Analytics, Akoya Biosciences, Visiopharm A/S, and Indica Labs, among others.

How This Report Helps

Provides accurate market size estimates and long-term forecasts for the computational pathology market.

Evaluates the impact of AI-driven image analysis on diagnostic accuracy and laboratory throughput.

Identifies high-growth opportunities across products and services, deployment modes, applications, end users, and geographic regions.

Analyzes emerging technology trends, regulatory developments, and innovation pipelines.

Benchmarks leading companies based on scanner and software integration, strategic initiatives, and competitive positioning.

Supports product development, investment planning, partnership evaluation, market entry, and business expansion strategies.

Delivers actionable market intelligence for medical device manufacturers, hospitals, pharmaceutical companies, investors, and consultants.

Key Questions Answered

What is the current size of the global computational pathology market, and how is it expected to evolve through 2036?

Which clinical, technological, and demographic factors are driving market growth?

What are the major drivers, restraints, opportunities, and challenges influencing industry development?

Which product and service, deployment mode, application, end-user, and regional segments are expected to experience the strongest growth?

Which geographic markets present the most attractive business opportunities?

Who are the leading companies operating in the market, and what competitive strategies are they adopting?

What recent product launches, partnerships, acquisitions, and technological innovations are shaping the competitive landscape?

How can stakeholders leverage market intelligence from this report to support investment decisions, product development, competitive benchmarking, and long-term business strategy?

TABLE OF CONTENTS

1. Market Definition & Scope

• 1.1. Market Definition
• 1.2. Market Ecosystem
• 1.3. Currency Considered
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
    • 2.3.1.1. Bottom-Up Approach
    • 2.3.1.2. Top-Down Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Assumptions for the Study

3. Executive Summary

• 3.1. Overview
• 3.2. Segmental Analysis
  • 3.2.1. Market Analysis, by Product & Service
  • 3.2.2. Market Analysis, by Deployment Mode
  • 3.2.3. Market Analysis, by Application
  • 3.2.4. Market Analysis, by End User
  • 3.2.5. Market Analysis, by Geography
• 3.3. Competitive Analysis

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Drivers
    • 4.2.1.1. Rising Incidence of Cancer and Increasing Diagnostic Workload
    • 4.2.1.2. Critical Shortage of Specialized Pathologists Globally
    • 4.2.1.3. Technological Advancements in AI and Deep Learning Models
  • 4.2.2. Restraints
    • 4.2.2.1. High Capital Investment for Scanners and Computing Infrastructure
    • 4.2.2.2. Complex and Evolving Regulatory Landscapes for Clinical AI
  • 4.2.3. Opportunities
    • 4.2.3.1. Integration with Multi-Omics Data for Holistic Precision Medicine
    • 4.2.3.2. Expansion into Rapidly Modernizing Emerging Markets in APAC and LATAM
  • 4.2.4. Challenges
    • 4.2.4.1. Lack of Standardized Image Formats Across Different Manufacturers
    • 4.2.4.2. Data Security and Privacy Concerns for Massive Patient Datasets
  • 4.2.5. Trends
    • 4.2.5.1. Shift Toward Cloud-Based SaaS Models for Scalability and Collaboration
    • 4.2.5.2. Increasing Regulatory Approvals for AI in Primary Clinical Diagnosis
• 4.3. Porter's Five Forces Analysis
• 4.4. Regulatory Landscape
• 4.5. Value Chain Analysis

5. Global Computational Pathology Market, by Product & Service

• 5.1. Overview
• 5.2. Software
  • 5.2.1. Whole Slide Imaging (WSI) Software
  • 5.2.2. AI-based Image Analysis Software
  • 5.2.3. Case Management Systems
• 5.3. Services
  • 5.3.1. Consulting & Implementation
  • 5.3.2. Training & Technical Support

6. Global Computational Pathology Market, by Deployment Mode

• 6.1. Overview
• 6.2. On-premise
• 6.3. Cloud-based (SaaS)

7. Global Computational Pathology Market, by Application

• 7.1. Overview
• 7.2. Drug Discovery & Development
• 7.3. Clinical Diagnostics
• 7.4. Education & Research

8. Global Computational Pathology Market, by End User

• 8.1. Overview
• 8.2. Hospitals & Diagnostic Labs
• 8.3. Pharmaceutical & Biotechnology Companies
• 8.4. Academic & Research Institutes

9. Global Computational Pathology Market, by Geography

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. U.K.
  • 9.3.3. France
  • 9.3.4. Netherlands
  • 9.3.5. Italy
  • 9.3.6. Rest of Europe
• 9.4. Asia-Pacific
  • 9.4.1. China
  • 9.4.2. Japan
  • 9.4.3. India
  • 9.4.4. South Korea
  • 9.4.5. Rest of Asia-Pacific
• 9.5. Latin America
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America
• 9.6. Middle East & Africa

10. Competitive Landscape

• 10.1. Overview
• 10.2. Key Growth Strategies
• 10.3. Competitive Dashboard
• 10.4. Vendor Market Positioning
• 10.5. Market Share Analysis, 2025

11. Company Profiles

• 11.1. Roche (Ventana Medical Systems)
• 11.2. Danaher Corporation (Leica Biosystems)
• 11.3. Siemens Healthineers AG
• 11.4. GE HealthCare Technologies Inc.
• 11.5. Philips Healthcare
• 11.6. Nikon Corporation
• 11.7. Olympus Corporation (Evident)
• 11.8. Hamamatsu Photonics K.K.
• 11.9. Proscia Inc.
• 11.10. Paige.AI
• 11.11. PathAI
• 11.12. Ibex Medical Analytics
• 11.13. Akoya Biosciences, Inc.
• 11.14. Visiopharm A/S
• 11.15. Indica Labs, Inc.

12. Appendix